secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0000950170-24-095072
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Q2 net loss $2.9M; FDA demands more data before COYA 302 ALS Phase 2
-------------------------------------------------------------------------

- Net loss $2.9M vs $3.1M YoY; collaboration rev $3.4M from Dr. Reddy's.
- Cash $36.6M at June 30, 2024.
- FDA requires additional non-clinical data before Phase 2 of COYA 302 in ALS; Coya plans to discuss in Q4 2024.
- Received $5M strategic investment from ADDF for COYA 302 in FTD.
- R&D expenses $4.6M (up from $1.1M) driven by preclinical costs for COYA 302.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000095017024095072/0000950170-24-095072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000095017024095072/coya-20240812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer